KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

A Population Pharmacokinetic and Exposure-Response Analysis for Baricitinib in Pediatric Patients with Atopic Dermatitis.

Rodney L Decker, C Steven Ernest, David B Radtke, Apurva Prakash, Xin Zhang

Clin Pharmacokinet 65(1) 119-131

PMID41212510
PMCIDPMC12783266
DOI10.1007/s40262-025-01563-8
发表日期2025-11-10
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:Fig. 1:非 KM 图;Fig. 2:AI 判定为 other;Fig. 3:非 KM 图;Fig. 4:非 KM 图;Fig. 5:非 KM 图。
摘要

摘要

BACKGROUND: Baricitinib is approved for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy and has received regulatory authorization in Europe for moderate-to-severe AD in patients 2 to <18 years. OBJECTIVE: This study aims to optimize dosing for baricitinib in pediatric patients with atopic dermatitis using pharmacokinetic/pharmacodynamic modeling leveraging adult data. METHODS: The phase III, randomized, double-blind, placebo-controlled study, BREEZE-AD-PEDS (NCT03952559, registration date: 2019-05-16), enrolled patients (aged 2 to <18 years) with moderate-to-severe AD. During a pharmacokinetic (PK) lead-in period, baricitinib concentration data from age-based dose cohorts (4 mg once daily [QD]: 10 to <18 years; 2 mg QD: 2 to <10 years) were compared with actual and simulated concentration values from adult patients receiving baricitinib 4 mg QD. A population PK model incorporating allometric scaling was developed to determine weight-based dosing in pediatric patients that matches adult exposures. The exposure-response (E-R) relationships were analyzed for the primary endpoint: a validated Investigator Global Assessment® (vIGA-AD) score of 0 or 1 (clear to almost clear skin) with ≥2-point improvement from baseline at week 16. Baricitinib pharmacokinetics were characterized from 393 pediatric patients using a 2-compartment model with allometric scaling on clearance and volume of distribution. RESULTS: The age-based and subsequent weight-based dosing (2 mg for patients 10 to <30 kg and 4 mg for patients ≥30 kg) was comparable to the 4-mg adult exposure. A clear E-R relationship was observed for the primary endpoint when sorted for age or weight groups. CONCLUSION: The population PK model developed using baricitinib concentrations from adult patients, with allometric scaling for weight on clearance and volume, adequately predicted exposures in the pediatric population. The PK modeling, with E-R analysis, informed an appropriate weight-based dosing regimen.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Comparison of observed plasma concentrations of baricitinib in pediatric patients in all age groups with AD from the BREEZE-AD-PEDS study and plasma concentrations in adult patients with AD receiving baricitinib 4 mg once daily. AD atopic dermatitis, QD once daily. A Pediatric participants aged 10 to <18 years ( N = 20) with AD receiving baricitinib 4 mg QD. B Pediatric participants aged 6 to <10 years ( N = 7) with AD receiving baricitinib 2 mg QD. C Pediatric participants aged 2 to <6 years ( N = 6) with AD receiving baricitinib 2 mg QD. Note: Black solid line and dashed lines are population pharmacokinetic model-estimated median with 90% prediction interval of concentrations, and gray circles are observed concentrations at 4 mg QD in adult patients with AD. Colored lines and symbols are for individual pediatric patients from BREEZE-AD-PEDS
非 KM Figure
Fig. 2Boxplots of simulated post-hoc A C max,ss and B AUC τ,ss at 4 mg QD by weight ranges, in pediatric patients with AD compared with adult patients with AD. AD atopic dermatitis, AUC τ,ss area under the concentration-versus-time curve during 1 dosing interval at steady state, C max,ss maximum observed drug concentration during a dosing interval at steady state, PK pharmacokinetics, QD once daily. Note: Boxes for adult AD are based on PK modeling with data combined from three phase II and phase III studies in adult patients with AD
非 KM Figure
Fig. 3Boxplots of simulated post-hoc A C max,ss and B AUC τ,ss at 2 mg QD for pediatric patients with AD <30 kg, and 4 mg QD for patients ≥30 kg, compared with adult patients with AD. Observed actual and dose-normalized post-hoc data overlaid. AD atopic dermatitis, AUC τ,ss area under the concentration versus time curve during a dosing interval at steady-state, C max,ss maximum observed drug concentration at steady-state, QD once daily. Box for adult AD is based on PK modeling with data combined from three phase II and phase III studies, in adult patients with AD. Grey circles = 4-mg dose normalized adult AD individual post-hoc estimates. Observed data dose normalized to 2 or 4 mg if the patient received a different dose. Black circles = 4 mg, blue triangles = 2 mg, green squares = 1 mg, and red diamonds = 0.5 mg
非 KM Figure
Fig. 4Exposure-response analysis: observed vIGA-AD ® 0 or 1 at Week 16 by baricitinib average plasma concentration at steady-state ( C av,ss ) quartiles for patients receiving placebo or baricitinib 0.5, 1, 2, or 4 mg once daily in BREEZE-AD-PEDS. C av,ss average concentration during a dosing interval at steady state, IGA Investigator’s Global Assessment, N number of subjects analyzed, NA not applicable, Q quartile. Note: Light blue bars indicate response rate
非 KM Figure
Fig. 5Exposure-response analysis by A patients <30 kg and B patients ≥30 kg bodyweight: observed IGA 0 or 1 at Week 16 by baricitinib average plasma concentration at steady-state ( C av,ss ) quartiles for patients receiving placebo or baricitinib 0.5, 1, 2, or 4 mg once daily in BREEZE-AD-PEDS. C av,ss average concentration during a dosing interval at steady state, IGA Investigator’s Global Assessment, N number of subjects analyzed, NA not applicable, Q quartile. Note: Light blue bars indicate response rate
非 KM Figure